Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 6, 2017Gene TherapyOpen Access

Strategy to detect pre-existing immunity to AAV gene therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

LFLillian FalesePennsylvania HospitalKSKrystal SandzaBioMarin (United States)BYBridget YatesBrigham and Women's Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Falese et al. (2017) studied this question.

synapsesocial.com/papers/6a09944e16dfdfe7ed3433d8https://doi.org/10.1038/gt.2017.95
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Determination of Anti-Adeno-Associated Virus Vector Neutralizing Antibody Titer with an In Vitro Reporter System2015 · 115 citations
  2. 2Prevalence of Neutralizing Antibodies Against Adeno-Associated Virus (AAV) Types 2, 5, and 6 in Cystic Fibrosis and Normal Populations: Implications for Gene Therapy Using AAV Vectors2006 · 226 citations
  3. 3Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue2012 · 138 citations
  4. 4Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents2011 · 348 citations